AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence